Melinta reports Phase I data for acne candidate radezolid

Melinta Therapeutics Inc. (New Haven, Conn.) reported data from a Phase I trial in 10 patients with mild to moderate acne vulgaris showing that twice-daily topical radezolid (RX-1741) for 4 weeks was well tolerated with minimal systemic absorption...